Short update on docosapentaenoic acid: a bioactive long-chain n-3 fatty acid

Current Opinion in Clinical Nutrition and Metabolic Care
Gunveen KaurA J Sinclair

Abstract

Docosapentaenoic acid (DPA) is a long-chain n-3 polyunsaturated fatty acid that is intermediary between eicosapentaenoic acid and docosahexaenoic acid in the n-3 synthesis pathway. DPA is part of our normal diet through fish and lean red meat. In recent years, DPA has received increasing attention as an important bioactive fatty acid in light of its potential beneficial health effects, which include anti-inflammatory actions, antiplatelet aggregation, and improved plasma lipid prolife. This review provides a short summary of the most recent research on DPA. In this review, we report on the latest association data as well as data generated from in-vitro and in-vivo studies on DPA and cardiovascular health, mental health, inflammation, and cancer. We also report on the newly identified DPA metabolites and their effects on exacerbation of inflammation in animal models. Although there is a growing body of evidence supporting DPA's role as an important bioactive fatty acid, there is a need for more 'cause and effect studies', clinical trials and studies which can reveal whether DPA plays separate roles to those identified for eicosapentaenoic acid and docosahexaenoic acid.

References

Jul 27, 2010·Progress in Lipid Research·Gunveen KaurAndrew J Sinclair
Feb 23, 2013·Journal of Psychiatric Research·Ameer Y TahaJagadeesh S Rao
Feb 26, 2013·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Kaisa M LinderborgAndrew J Sinclair
Jun 6, 2013·Scientific Reports·Jesmond DalliCharles N Serhan
Nov 19, 2013·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Samaneh Ghasemi FardAndrew J Sinclair
Jun 16, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Caroline MorinSamuel Fortin
Jun 23, 2015·Lipid Technology·Oleksandr A ByelashovGunveen Kaur

❮ Previous
Next ❯

Citations

Feb 12, 2019·Cancer Medicine·Jiaqing LiuLi Zhang
Oct 5, 2019·Nutrients·Theresa GreupnerJan Philipp Schuchardt
Dec 15, 2018·Current Opinion in Clinical Nutrition and Metabolic Care·Kevin C Maki, Mary R Dicklin
Aug 10, 2019·European Journal of Clinical Nutrition·Lucinda J BlackUNKNOWN Ausimmune Investigator Group
Jul 1, 2020·International Journal of Molecular Sciences·Adriana R SilvaCassiano F Gonçalves-de-Albuquerque
Jul 1, 2020·Frontiers in Plant Science·James R PetrieSurinder P Singh
Nov 20, 2019·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Xiao-Fei GuoDuo Li
Jun 13, 2017·Prostaglandins & Other Lipid Mediators·Trond Vidar HansenCharles N Serhan

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.